Drug intelligence / Profile preview

(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol

Development stage
Unknown
Modality
Small Molecules
01

Overview

(2R)-2‑({9‑(1‑methylethyl)‑6‑[(4‑pyridin‑2‑ylbenzyl)amino]‑9H purin–2–yl}amino)butan–1–ol, also known as CR8 or RC8, is a synthetic small molecule and a purine derivative. It is an experimental compound primarily studied as a cyclin-dependent kinase inhibitor, with selectivity for cyclin-dependent kinase 2 (CDK2). CDK inhibitors are of interest in oncology and cell cycle research due to their ability to modulate cell proliferation by interfering with the activity of kinases essential for cell cycle progression. The compound has been used in preclinical studies but does not have approved therapeutic indications at this time[1][7][9].

Other names
(2R)-2-{[9-(propan-2-yl)-6-{[4-(pyridin-2 yl)phenyl]methyl}amino}-9H-purin 2 yl]amino}butan 1 ol(R)-2-(9-Isopropyl 6-(4-(pyridin 2 yl)benzylamino) 9H purin 2 yl amino)butan 1 olC&R8
02

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call